Abstract
CD40-CD40L interaction plays a significant role in the pathogenesis of atherosclerosis and coronary artery disease. The clinical predictive value of Soluble CD40 Ligand (sCD40L) was evaluated in patients with Acute Coronary Syndrome (ACS) and Non-Cardiac Chest Pain (NCCP). The levels of serum soluble CD 40 ligand were measured by ELISA in 485 patients admitted to emergency care unit, of which 89 patients were diagnosed as NCCP. The levels of sCD40L were significantly increased in patients with ACS when compared to controls and NCCP. Receiver Operator Characteristic (ROC) Curve analysis showed sCD40L to be a good discriminator between patients with ischemic heart disease and patients without ischemic heart disease. The area under the curve was found to be 0.940 with 95% CI (0.915 to 0.960) (P<0.0001). The cut off value from the ROC curve was 2.99 ng/ml, above which sCD40L was considered to be positive. Combined assessment of sCD40L, Troponin I and CK-MB enhanced the risk prediction and early classification of patients. sCD40L seems to be a promising biomarker for identification and risk stratification for patients with acute coronary syndrome.
Key Words: sCD40L, Atherosclerosis, Acute coronary syndrome, Biomarker
Full Text
The Full Text of this article is available as a PDF (160.0 KB).
References
- 1.Henn V., Slupsky J.R., Grafe M., Anagnostopoulos I., Forster R., Muller-Berghaus G., Kroczek R.A. CD40 Ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature. 1998;391:591–594. doi: 10.1038/35393. [DOI] [PubMed] [Google Scholar]
- 2.Aukrust P., Muller F., Ueland Thor B.S., Berget T., Aaser E., Brunsvig B.S., et al. Enhanced levels of soluble and membrane bound CD40 Ligand in platelets with unstable angina. Circulation. 1999;100:614–620. doi: 10.1161/01.cir.100.6.614. [DOI] [PubMed] [Google Scholar]
- 3.Mach F., Schonbeck U., Libby P. CD 40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis. 1998;137(suppl):s89–95. doi: 10.1016/S0021-9150(97)00309-2. [DOI] [PubMed] [Google Scholar]
- 4.Lemos J.A., Zirlik A., Schonbeck U., Varo N., Murphy S.A., Kera A., et al. Associations between soluble CD40 Ligand, Atherosclerosis Risk Factors and Subclinical Atherosclerosis. Results from the Dallas Heart Study. Arteriosclerosis, Thromb Vascular biol. 2005;25:2192–2196. doi: 10.1161/01.ATV.0000182904.08513.60. [DOI] [PubMed] [Google Scholar]
- 5.Chai H., Yan S., Wang H., Zhang R., Lin P.H., Yao Q., Chen C. CD 40 ligand increases expression of its receptor CD40 in human coronary artery endothelial cells. Surgery. 2006;140:236–242. doi: 10.1016/j.surg.2006.03.016. [DOI] [PubMed] [Google Scholar]
- 6.Heeschen C., Dimmeler S., Hamm C.W., Brand M.J., Boersma E., Zeiher A.M., Simoons M.L., CAPTURE Study Investigators Soluble CD40 Ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104–1111. doi: 10.1056/NEJMoa022600. [DOI] [PubMed] [Google Scholar]
- 7.Santilli F., Basili S., Ferroni P., Davi G. CD40/CD40L system and vascular disease. Inter Emerg Med. 2007;2:256–268. doi: 10.1007/s11739-007-0076-0. [DOI] [PubMed] [Google Scholar]
- 8.Varo N., Lemos J. A., Libby P., Morrow D.A., Murphy S.A., Nuzzo R., et al. Soluble CD40L risk prediction after acute coronary syndromes. Circulation. 2003;108:1049–1052. doi: 10.1161/01.CIR.0000088521.04017.13. [DOI] [PubMed] [Google Scholar]
- 9.Henn V., Steinbach S., Buchner K., Presek P., Kroczek R.A. The inflammatory action of CD40 ligand expressed on activated human platelets is temporally limited by coexpressed CD40. Blood. 2001;98:1047–1054. doi: 10.1182/blood.V98.4.1047. [DOI] [PubMed] [Google Scholar]
- 10.Mach F., Schonbeck U., Bonnefoy J.Y., Pober J.S., Libby P. Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40:Induction of collagenase stromyelysin and tissue factor. Circulation. 1997;96:396–399. doi: 10.1161/01.cir.96.2.396. [DOI] [PubMed] [Google Scholar]
- 11.Miller D.L., Yaron R., Yellin M.J. CD40L-CD40 interactions regulate endothelial cell surface tissue factor and thrombomodulin expression. J Leukoc Biol. 1998;63:373–379. doi: 10.1002/jlb.63.3.373. [DOI] [PubMed] [Google Scholar]
- 12.Michelson A.D., Barnard M.R., Krueger C.A., Valeri C.R., Furman M.I. Circulating monocyte — platelet aggregates are a more sensitive marker of in vivo platelet activation than platelet surface P-Selectin: Studies in baboons, human coronary intervention and human acute myocardial infarction. Circulation. 2001;104:1533–1537. doi: 10.1161/hc3801.095588. [DOI] [PubMed] [Google Scholar]
- 13.Yan J.-C., Zhu J., Gao L., Wu Z.G., Kong X.T., et al. The effect of elevated serum soluble CD40 ligand on the prognostic value in patients with acute coronary syndrome. Clin Chim Acta. 2004;343:155–159. doi: 10.1016/j.cccn.2004.01.012. [DOI] [PubMed] [Google Scholar]
- 14.Weber M., Rabenau B., Stanisch M., Nef H.M., Mollmann H., et al. Influence of sample type on soluble CD40 ligand assessment in patients with acute coronary syndromes. Thromb Res. 2007;120:811–814. doi: 10.1016/j.thromres.2007.01.014. [DOI] [PubMed] [Google Scholar]
- 15.Ahn R.E., Lander G., Jy W., Bidot J.C., Jimenez J.J., Horstman L.L., Ahn S.Y. Differences of soluble CD40L in sera and plasma: Implications of CD40L as a marker of thrombotic risk. Thromb Res. 2004;114:143–148. doi: 10.1016/j.thromres.2004.06.005. [DOI] [PubMed] [Google Scholar]
- 16.Tsuzuki M., Morishima I., Yoshida T., Hayashi Y., Miura M., Hirai T., et al. Inverse correlation between soluble CD40 ligand and soluble CD40 is absent in patients with unstable angina. Heart Vessels. 2005;20:245–250. doi: 10.1007/s00380-005-0840-x. [DOI] [PubMed] [Google Scholar]
- 17.Ivandic T.B., Spanuth E., Hasse D., Lestin H.G., Katus A.H. Increased plasma concentrations of sCD40L in acute coronary syndrome depend on in vitro platelet activation. Clin Chem. 2007;53(7):1231–1234. doi: 10.1373/clinchem.2007.085332. [DOI] [PubMed] [Google Scholar]